This Report is the fifth integrated report prepared by Pelion S.A., presenting information on both financial and non-financial performance of Pelion S.A. and its subsidiaries. By integrating financial and non-financial disclosures, we provide a picture of how Pelion manages its social impacts and creates value through various fields of its activity. This Report covers the period from January 1st to December 31st 2016. It was prepared in accordance with GRI G4, in the core option, using the International Integrated Reporting
This Report covers the Pelion Group comprising the companies presented in the consolidated financial statements (see “Detailed financial and non-financial disclosures”), namely the Group's Parent, that is the holding company Pelion S.A., and the following companies: Polska Grupa Farmaceutyczna S.A., Pharmapoint Sp. z o.o., PGF Urtica sp. z o.o., DOZ S.A., UAB NFG (registered in Lithuania), Natura Sp. z o.o. (Drogerie Natura), Consensus sp. z o.o., Business Support Solution S.A., epruf S.A., ALE sp. z o.o., Eubioco S.A., Pharmena S.A., and Szpital Specjalistyczny Brzeziny (Brzeziny Specialist Hospital).
The reliability of this Report and its compliance with the Guidelines were supervised by an external expert, who assisted in its preparation. However, this Report has not been subject to independent verification.